Limited Sampling Strategy for the Prediction of Area Under the Curve (AUC) of Statins: Reliability of a Single Time Point for AUC Prediction for Pravastatin and Simvastatin

Abstract

Statins are widely prescribed medicines and are also available in fixed dose combinations with other drugs to treat several chronic ailments. Given the safety issues associated with statins it may be important to assess feasibility of a single time concentration strategy for prediction of exposure (area under the curve; AUC). The peak concentration (C_max) was used to establish relationship with AUC separately for pravastatin and simvastatin using published pharmacokinetic data. The regression equations generated for statins were used to predict the AUC values from various literature references. The fold difference of the observed divided by predicted values along with correlation coefficient (r) were used to judge the feasibility of the single time point approach. Both pravastatin and simvastatin showed excellent correlation of C_max vs. AUC values with r value≥0.9638 (p<0.001). The fold difference was within 0.5-fold to 2-fold for 220 out of 227 AUC predictions and >81% of the predicted values were in a narrower range of >0.75-fold but <1.5-fold difference. Predicted vs. observed AUC values showed excellent correlation for pravastatin (r=0.9708, n=115; p<0.001) and simvastatin (r=0.9810; n=117; p<0.001) suggesting the utility of C_max for AUC predictions. On the basis of the present work, it is feasible to develop a single concentration time point strategy that coincides with C_max occurrence for both pravastatin and simvastatin from a therapeutic drug monitoring perspective.

Key words

pravastatin - simvastatin - pharmacokinetics - peak concentration - AUC - correlation - limited sampling strategy - therapeutic drug monitoring - statins

• References

• 1 Gu Q, Paulose-Ram R, Burt VL et al. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. NCHS Data Brief 2014; 177: 1-8
• 2 Rodriguez AprilL, Brandon M et al. Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis 2012; 33: 371-382
• 3 Aarnio E, Korhonen MJ, Huupponen R et al. Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence – estimates from the Finnish prescription register. Atherosclerosis 2015; 239: 240-247
• 4 Bush JR, Bérubé NG, Beier F. A new prescription for growth? Statins, cholesterol and cartilage homeostasis. Osteoarthritis Cartilage 2015; 23: 503-506
• 5 Blum A. HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells-New mechanistic insights of atherosclerosis. Biofactors 2014; 40: 295-302
• 6 Hayashi T, Kubota K, Kawashima S et al. Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals. Int J Cardiol 2014; 177: 860-866
• 7 Hobbs T, Caso R, McMahon D et al. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study. Altern Ther Health Med 2014; 20: 18-23
• 8 Selak V, Elley CR, Bullen C et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014; 348: g3318
• 9 Farnier M, Retterstol K, Steinmetz A et al. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy andsimvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease. Diab Vasc Dis Res 2012; 9: 205-215
• 10 Castellano JM, Sanz G, Peñalvo JL et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014; 64: 2071-2082
• 11 Watanabe JH, Bounthavong M, Chen T et al. Association of polypharmacy and statin new-user adherence in a Veterans Health Administration population: a retrospective cohort study. Ann Pharmacother 2013; 47: 1253-1259
• 12 Gillett Jr RC, Norrell A. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Am Fam Physician 2011; 83: 711-716
• 13 Finks SW, Campbell JD. Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm. Nurse Pract 2014; 39: 45-51
• 14 Kellick KA, Bottorff M, Toth PP. The National Lipid Association’s Safety Task Force. A clinician’s guide to statin drug-drug interactions. J Clin Lipidol 2014; 8: S30-S46
• 15 Mueller SC, Drewelow B. Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies. Eur J Clin Pharmacol 2013; 69: 1127-1134
• 16 Huang JH, Wang K, Huang XH et al. Limited sampling strategy models for estimating the AUC of gliclazide in Chinese healthy volunteers. Eur J Drug Metab Pharmacokinet 2013; 38: 123-130
• 17 Lawson EB, Wu JC, Baldwin RM et al. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. Eur J Clin Pharmacol 2012; 68: 407-413
• 18 Azie NE, Brater DC, Becker PA et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369-377
• 19 Mousa O, Brater DC, Sunblad KJ et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267-274
• 20 Howgate EM, Rowland Yeo K et al. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 2006; 36: 473-497
• 21 Chen Y, Mao J, Hop CE. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone. Drug Metab Dispos 2015; 43: 182-189
• 22 Benjamin B, Sahu M, Bhatnagar U et al. The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds?. Arzneimittelforschung 2012; 62: 194-201
• 23 Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006; 80: 356-366
• 24 Wu LX, Guo CX, Chen WQ et al. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. Br J Clin Pharmacol 2012; 73: 750-757
• 25 Keskitalo JE, Kurkinen KJ, Neuvonen M et al. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009; 68: 207-213
• 26 Hedman M, Antikainen M, Holmberg C et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 2006; 61: 706-715
• 27 Aberg JA, Rosenkranz SL, Fichtenbaum CJ et al. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS 2006; 20: 725-729
• 28 Fukazawa I, Uchida N, Uchida E et al. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol 2004; 57: 448-455
• 29 Kyrklund C, Backman JT, Neuvonen M et al. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2004; 57: 181-187
• 30 Triscari J, Swanson BN, Willard DA et al. Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 1993; 36: 263-265
• 31 Pan HY, Triscari J, DeVault AR et al. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 1991; 31: 665-670
• 32 Singhvi SM, Pan HY, Morrison RA et al. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990; 29: 239-243
• 33 Aquilante 1 CL, Kiser JJ, Anderson PL et al. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol 2012; 52: 1725-1738
• 34 Ogawa K, Hasegawa S, Udaka Y et al. Individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects. J Clin Pharmacol 2003; 43: 1268-1273
• 35 Derks M, Abt M, Phelan M et al. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 2010; 50: 1188-1201
• 36 Gustavson LE, Schweitzer SM, Koehne-Voss S et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. J Clin Pharmacol 2005; 45: 947-953
• 37 Halstenson CE, Triscari J, DeVault A et al. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992; 32: 124-132
• 38 Kovarik JM, Hartmann S, Hubert M et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002; 42: 222-228
• 39 Pan HY, DeVault AR, Wang-Iverson D et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30: 1128-1135
• 40 Pan WJ, Gustavson LE, Achari R et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000; 40: 316-323
• 41 Pentikainen PJ, Saraheimo M, Schwartz JI et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992; 32: 136-140
• 42 Hulskotte EG, Feng HP, Xuan F et al. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin andpravastatin. Antimicrob Agents Chemother 2013; 57: 2582-2588
• 43 Ieiri I, Tsunemitsu S, Maeda K et al. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. J Clin Pharmacol 2013; 53: 654-661
• 44 Deng S, Chen XP, Cao D et al. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. Clin Ther 2009; 31: 1256-1263
• 45 Wiersma HE, Wiegman A, Koopmans RP et al. Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia. Clin Drug Investig 2004; 24: 113-120
• 46 Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341
• 47 Olbricht C, Wanner C, Eisenhauer T et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311-321
• 48 Igel M, Arnold KA, Niemi M et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 2006; 79: 419-426
• 49 Hedman M, Neuvonen PJ, Neuvonen M et al. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004; 75: 101-109
• 50 Park JW, Siekmeier R, Merz M et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther 2002; 40: 439-450
• 51 Niemi 1 M, Schaeffeler E, Lang T et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429-440
• 52 O’Brien SG, Meinhardt P, Bond E et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003; 89: 1855-1859
• 53 Krishna R, Garg A, Jin B et al. Assessment of a pharmacokinetic and pharmacodynamic interaction betweensimvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 2009; 67: 520-526
• 54 Bernsdorf A, Giessmann T, Modess C et al. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 2006; 61: 440-450
• 55 Kosoglou T, Meyer I, Veltri EP et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002; 54: 309-319
• 56 Hsyu PH, Schultz-Smith MD et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45: 3445-3450
• 57 Ziviani L, Da Ros L, Squassante L et al. The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. Br J Clin Pharmacol 2001; 51: 147-152
• 58 Bergman AJ, Murphy G, Burke J et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44: 1054-1062
• 59 Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004; 58: 56-60
• 60 Zhi J, Moore R, Kanitra L et al. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol 2003; 43: 428-435
• 61 Ding MJ, Yuan LH, Li Y et al. Pharmacokinetics and Bioequivalence Study of Simvastatin Orally Disintegrating Tablets in Chinese Healthy Volunteers by LC-ESI-MS/MS. J Bioequiv Availab 2011; 3: 032-037
• 62 Pasanen MK, Neuvonen M, Neuvonen PJ et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16: 873-879
• 63 Kasichayanula S, Chang M, Liu X et al. Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin. Advances in Therapy 2012; 29: 163-177
• 64 Falcão A, Pinto R, Nunes T et al. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res 2013; 106: 244-249
• 65 Winsemius A, Ansquer JC, Olbrich M et al. Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter? Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?. J Clin Pharmacol 2014; 54: 1038-1047
• 66 Liu M, Wang XL, Zhang D et al. Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. Drug Res (Stuttg) 2014; 64: 296-300
• 67 Zhou Q, Ruan ZR, Jiang B et al. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Pharmazie 2013; 68: 124-128
• 68 Chu NN, Chen WL, Xu HR et al. Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. Clin Drug Investig 2012; 32: 791-798
• 69 Patel CG, Li L, Girgis S et al. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol 2011; 3: 13-25
• 70 Prueksaritanont T, Vega JM, Zhao J et al. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 2001; 41: 573-581
• 71 Kim KA, Park PW, Lee OJ et al. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007; 47: 87-93
• 72 Stoll 1 F, Burhenne J, Lausecker B et al. Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. J Clin Pharmacol 2013; 53: 1199-1204
• 73 Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477-483
• 74 Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341
• 75 DeGorter 1 MK, Urquhart BL, Gradhand U et al. Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. J Clin Pharmacol 2012; 52: 1689-1697
• 76 Nishio S, Watanabe H, Kosuge K et al. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 2005; 28: 223-227
• 77 Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-182
• 78 Zhou Q, Ruan ZR, Jiang B et al. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Pharmazie 2013; 68: 124-128
• 79 Jin SJ, Bae KS, Cho SH et al. Population pharmacokinetic analysis of simvastatin and its active metabolite with the characterization of atypical complex absorption kinetics. Pharm Res 2014; 31: 1801-1812
• 80 Posvar EL, Radulovic LL, Cilla Jr DD et al. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol 1996; 36: 728-731
• 81 Xu HR, Chen WL, Chu NN et al. The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. J Biomed Biotechnol 2012; 2012 386230